Europe EV-Based Liquid Biopsy Market Report 2023-2032: Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs Driving Developments

DUBLIN, Jan. 17, 2024 /PRNewswire/ -- The "Europe EV-Based Liquid Biopsy Market - Analysis and Forecast, 2023-2032" report has been added to  ResearchAndMarkets.com's offering.

The Europe EV-based liquid biopsy market was valued at $18.88 million in 2022 and is anticipated to reach $115.34 million by 2032, witnessing a CAGR of 20.30% during the forecast period 2023-2032.

The Europe EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease. The field of healthcare diagnostics has been revolutionized by its non-invasiveness, real-time monitoring capabilities, and potential for early disease diagnosis.

EV-based liquid biopsy has improved patient outcomes, decreased expenses associated with healthcare, and provided a less intrusive and more accessible means of monitoring and diagnosing diseases, including cancer. Furthermore, the market expansion is anticipated to be aided by the entry of many established companies, including Bio-Techne Corporation, QIAGEN N.V., and Thermo Fisher Scientific Inc.

In addition, the market expansion for EV-based liquid biopsies has created economic opportunities, prompted industrial participants to collaborate with academic institutions, and sparked research and development efforts.

How can this report add value to an organization?

Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of EVs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.

Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Analyst's Perspective on EV-Based Liquid Biopsy Market

The EV-based liquid biopsy market is experiencing rapid growth due to the use of EV-based liquid biopsy in both clinical and research settings, primarily focused on detecting and monitoring prostate, pancreatic, ovarian, lung, and bladder cancers. Further, the amplified funding and dedicated research efforts in EV-based liquid biopsy market is a major driver of market growth.

In recent years, there has been a significant increase in the amount of funding being directed toward EV-based liquid biopsy research. This is due to the growing recognition of the potential of EVs to revolutionize cancer diagnostics. Therefore, the impact of the aforementioned factors is expected to drive the EV-based liquid biopsy market in the near future.

Key Questions Answered in the Report

• What is EV-based liquid biopsy?
• What is the market size and future potential of Europe EV-based liquid biopsy?
• What are the major market drivers, challenges, and opportunities and their respective impacts in the Europe EV-based liquid biopsy market?
• What are the key development strategies that have been implemented by the major players in order to sustain the competitive market?

Key Market Players and Competition Synopsis

• Abcam plc
• Qiagen N.V.
• Malvern Panalytical Ltd
• Lonza Group AG

Key Topics Covered:

1 Definition
1.1 Inclusion and Exclusion Criteria

2 Research Scope
2.1 Key Questions Answered in the Report:

3 Research Methodology
3.1 EV-Based Liquid Biopsy Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Markets Overview
4.1 Market Introduction
4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
4.3 Current Market Size and Growth Potential, $Million, 2022-2032
4.4 COVID-19 Impact on EV-based Liquid Biopsy Market
4.4.1 Impact on Operations
4.4.2 COVID-19 Impact: Current Scenario of the Market

5 Methods of EV Isolation and Analysis
5.1 Overview
5.1.1 Evs Introduction
5.2 Isolation Methods
5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
5.2.1.1 Differential Ultracentrifugation
5.2.1.2 Density Gradient Centrifugation
5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
5.2.1.4 Isopycnic Centrifugation
5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
5.2.2.1 Ultrafiltration
5.2.2.2 Sequential Filtration
5.2.2.3 Size Exclusion Chromatography (SEC)
5.2.2.4 Flow Field-Flow Fractionation (FFFF)
5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
5.2.3.2 Magneto-Immunoprecipitation
5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
5.2.4.1 Polyethylene Glycol (PEG) Precipitation
5.2.4.2 Lectin Induced Agglutination
5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
5.2.6 EV Isolation Techniques Utilizing Commercial Kits
5.2.7 Advantages and Disadvantages of the EV Isolation Methods
5.2.8 Novel Approaches for Exosome Isolation
5.3 Analysis Methods
5.3.1 Advantages and Disadvantages of Analysis Methods for Evs

6 Industry Insights
6.1 Overview
6.2 Legal Requirements in the U.S.
6.3 Legal Requirements and Frameworks in Europe
6.4 Legal Requirements and Frameworks in Asia-Pacific
6.5 Reimbursement Scenario

7 Market Dynamics
7.1 Overview
7.2 Impact Analysis
7.3 Market Drivers
7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
7.3.2 Amplified Funding and Dedicated Research Efforts
7.3.3 Rising Prevalence of Cancers
7.4 Market Restraints
7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
7.5 Market Opportunities
7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
7.5.2 Development of New EV-Based Biomarkers
7.5.3 Approved Products in the Market

8 EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
8.1 Overview
8.2 Europe
8.2.1 Germany
8.2.2 U.K.
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest-of-Europe

9 Company Profiles
9.1 Company Overview
9.1.1 Company Overview
9.1.2 Role in the EV-Based Liquid Biopsy Market
9.1.3 Major Products: Key Specifications
9.1.4 Key Competitors
9.1.5 Analyst Perspective

For more information about this report visit https://www.researchandmarkets.com/r/vewwgq

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets